The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function;Wpływ stosowania nowej, niskoestrogenowej tabletki antykoncepcyjnej zawieraja{ogonek}cej drospirenon na profil lipidowy, gospodarke{ogonek} we{ogonek}glowodanowa{ogonek} i czynność wa{ogonek}troby

Ginekologia Polska

Volumn 80, Issue 2, 2009, Pages 99-102

  Katarzyna, Szlendak Sauer ^a   Stanisław, Radowicki ^a   Katarzyna, Skórzewska ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Blood glucose; Contraceptives oral hormonal; Drospirenone; Lipids; Liver function tests

Indexed keywords

ANDROSTANE DERIVATIVE; ESTRADIOL; ESTRADIOL DROSPIRENONE COMBINATION; ESTRADIOL-DROSPIRENONE COMBINATION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; BLOOD; CARBOHYDRATE METABOLISM; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; LIVER; LIVER FUNCTION TEST; POLAND; WOMEN'S HEALTH;

ADULT; ANDROSTENES; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESTRADIOL; FEMALE; HUMANS; LIPID METABOLISM; LIPOPROTEINS; LIVER; LIVER FUNCTION TESTS; POLAND; PROGESTERONE CONGENERS; WOMEN'S HEALTH; YOUNG ADULT;

EID: 65349149945     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Hoffmann H, Moore C, Zimmermann H, [et al.]. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol. 1998, 50, 458-464.
2. Benagiano G, Bastianelli C, Farris M. Contraception Today. Ann NY Acad Sci. 2006, 1092, 1-32.
3. Apter D, Boros A, Baumgärtner, [et al.]. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003, 8, 37-51.
4. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000, 62, 29-38.
5. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties; a short review. Moll Cell Endocrinol. 2004, 217, 255-261.
6. Gaspard U, Scheen A, Endricat J, [et al.]. A randomized'study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception, 2003, 67, 423-429.
7. Oelkers W, Foidart J, Dombrovicz N, [et al.]. Effects of a new oral contraceptive containing an antimineralocorticoid progestagen, drospirenone, on the rennin-aldosteron system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995, 80, 1816-1820.
8. Parsey K, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000, 61, 105-111.
9. Klipping C, Marr J.; Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005, 71, 409-416.